SUPPLEMENTARY DATA

Treatment Arm	INO-1400 Dose (mg)	INO-1401 Dose (mg)	INO-9012 Dose (mg)
1	2.0		
2	8.0		
3	2.0		0.5
4	2.0		2.0
5	8.0		0.5
6	8.0		2.0
7		2.0	
8		8.0	
9		8.0	0.5
10		8.0	2.0

Supplementary Table 1- Study treatment arms

		Tumor Type								
		Pancreatic	Lung	Colorectal	Breast	Ovarian	H&N	Esophageal	HCC	Gastric
STAGE	I								1	
	IB	3	1							
	II		1						1	
	IIA	5	1		4					
	IIB	20	3		3					
	III	5		6	1					
	IIIA		7			1		1		1
	IIIB			1		2		1		
	IIIC			2	2	4				
	IV	1	1	5		1				
	IVA			4			2			
	IVB					1	1			
	TOTAL	34	14	18	10	9	3	2	2	1

Supplementary Table 2- Study demographics by disease and stage

System Organ Class Preferred Term	Subject Count (%) by Severity Grade	
	Grade 3	Grade 4
Any adverse events	15 (16.1%)	1 (1.1%)
Blood and lymphatic system disorders	1 (1.1%)	0 (0.0%)
Leukocytosis	1 (1.1%)	0 (0.0%)
Cardiac disorders	1 (1.1%)	0 (0.0%)
Acute coronary syndrome	1 (1.1%)	0 (0.0%)
Gastrointestinal disorders	5 (5.4%)	0 (0.0%)
Abdominal pain	1 (1.1%)	0 (0.0%)
Ascites	1 (1.1%)	0 (0.0%)
Diarrhoea	1 (1.1%)	0 (0.0%)
Ileus	1 (1.1%)	0 (0.0%)
Mouth haemorrhage	1 (1.1%)	0 (0.0%)
Obstruction gastric	1 (1.1%)	0 (0.0%)
Hepatobiliary disorders	1 (1.1%)	0 (0.0%)
Bile duct obstruction	1 (1.1%)	0 (0.0%)
Infections and infestations	4 (4.3%)	1 (1.1%)
Breast cellulitis	1 (1.1%)	0 (0.0%)
Cellulitis	2 (2.2%)	0 (0.0%)
Clostridium difficile colitis	1 (1.1%)	0 (0.0%)
Pneumonia	1 (1.1%)	0 (0.0%)
Sepsis	0 (0.0%)	1 (1.1%)
Injury, poisoning and procedural complications	3 (3.2%)	0 (0.0%)
Fall	1 (1.1%)	0 (0.0%)
Incisional hernia	1 (1.1%)	0 (0.0%)
Wound complication	1 (1.1%)	0 (0.0%)
Investigations	1 (1.1%)	0 (0.0%)
Lipase increased	1 (1.1%)	0 (0.0%)
Musculoskeletal and connective tissue disorders	1 (1.1%)	0 (0.0%)
Osteoarthritis	1 (1.1%)	0 (0.0%)
Renal and urinary disorders	1 (1.1%)	0 (0.0%)
Hydronephrosis	1 (1.1%)	0 (0.0%)
Skin and subcutaneous tissue disorders	1 (1.1%)	0 (0.0%)
Rash maculo-papular	1 (1.1%)	0 (0.0%)
Vascular disorders	1 (1.1%)	0 (0.0%)
Hypertension	1 (1.1%)	0 (0.0%)

Supplementary Table 3- Summary of Grade 3-4 Adverse Events (mITT population, N=93)



Supplementary Figure 1- Kaplan-Meier Analysis of Disease-Free Survival Across All Treatment Arms (mITT population, N=93)



Supplementary Figure 2- Time on Study from Diagnosis and from Day 0 (black bar) by Tumor Type (N=93)


A
Arm 1
2mg INO-1400
P=0.004
hTERT Specific IFN-γ SFU/10^6 PBMCs
PRE
POST
n=10
Arm 3
2mg INO-1400 + 0.5mg INO-9012
P=0.031
n=9
Arm 4
2mg INO-1400 + 2mg INO-9012
P=0.004
n=9
Arm 2
8mg INO-1400
P=0.031
n=10
Arm 5
8mg INO-1400 + 0.5mg INO-9012
P=0.031
n=8
Arm 6
8mg INO-1400 + 2mg INO-9012
P=0.031
n=9



Supplementary Figure 3- IFN-γ ELISpot responses broken out by study treatment arm. Open symbols represent individual patients, the box extends from the 25th to the 75th percentile, line inside the box is a the median, and the whiskers extend from the minimum to maximum values. A) Wilcoxon signs rank test was used to assess significance between the magnitude of IFN-g in patients before (PRE) and after (POST) immunotherapy. The number of patients in each group is displayed below the graph, n. B) The increase over baseline is shown for each group. Wilcoxon ranked sum test was used to assess significance of the increase over baseline between treatment groups. C) The increase over baseline is shown for subjects who have no hTERT specific IFN-g

detected by ELISpot at baseline (Baseline=0) or who had a detectable magnitude of hTERT specific IFN-g detected by ELISpot at baseline (Baseline>1).

Clinical Status of Pancreatic Cancer Subjects			
	Alive, NED	**Alive, Progressed or Disease Status Unknown**	**Deceased with Disease**
Subject ID	51018	51047	51050
	51021	51057	51019
	51010	51017	51061
	51059	51067	51045
	51051	51052	51042
	51037	51040	51060
	51029	51034	
	51028		
	51013		
	51002		

Supplementary Table 4- Clinical status as of the date of last contact of the subset of pancreatic cancer patients with long-term follow up